ABBV · 8-K · 20260731PR000023

Acquisition / Partnership / Divestiture

AbbVie Inc. · 2026-07-31 · Importance 71 · Surprise 60 · No source text

AbbVie entered a definitive agreement to acquire Apogee Therapeutics and its clinical-stage inflammatory and immunological disease pipeline. The transaction values Apogee at approximately $10.9 billion in total equity value and is expected to close in the third quarter of 2026. Key assets include late-stage IL-13 antibody zumilokibart (APG777) for atopic dermatitis and long-acting IL-13/TSLP combination candidate APG273 for asthma. The proposed acquisition is expected to reduce 2026 adjusted diluted EPS by $0.14 and deepen AbbVie’s immunology portfolio.

Key facts

• AbbVie announced a definitive agreement to acquire Apogee Therapeutics; the transaction values Apogee at a total equity value of approximately $10.9 billion and is expected to close in the third quarter of 2026. source
• The company's 2026 adjusted diluted EPS guidance includes an unfavorable impact of $0.58 per share related to acquired IPR&D and milestones expense incurred year-to-date through the second quarter 2026. source
• Reported GAAP acquired IPR&D and milestones expense for the six months ended June 30, 2026: $1,035 million. source
• The press release states the proposed Apogee acquisition includes zumilokibart (APG777) and APG273 and is expected to close in the third quarter of 2026. source
• Acquired IPR&D and milestones expense for the quarter ended June 30, 2026: $291 million (pre-tax). source
• Acquired IPR&D and milestones expense was 1.7 percent of net revenues in the second quarter. source
• The $3.65 adjusted diluted EPS result includes an unfavorable impact of $0.17 per share related to acquired IPR&D and milestones expense. source

Impact estimates